Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Anti-TNFα trumps other treatments at preventing postoperative Crohn’s disease recurrence

10 Aug 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Anti-tumour necrosis factor α (anti-TNFα) agents are better than other conventional therapies at preventing the clinical, endoscopic and histological postoperative recurrence (POR) of Crohn’s disease (CD), reports a recent meta-analysis.

After applying the selection criteria, 14 studies emerged eligible for inclusion in the analysis, ten of which were randomized controlled trials (RCTs) by design. The resulting cumulative sample included 1,224 CD patient. Studies were retrieved from the databases of PubMed, Embase, CENTRAL and Web of Science.

The rate of clinical (odds ratio [OR], 0.508, 95 percent CI, 0.309–0.834; p=0.007), endoscopic (OR, 0.312; 0.199–0.489; p<0.001), severe endoscopic (OR, 0.195, 0.195–0.356; p<0.001) and histological (OR, 0.255, 0.106–0.611) POR was significantly lower in patients who were taking anti-TNFα as opposed to other nonbiological treatments.

In comparison, anti-TNFα therapy was significantly better than thiopurines only in terms of endoscopic POR (OR, 0.392, 0.241–0.639; p<0.001). Head-to-head comparison studies also showed that adalimumab and infliximab resulted in statistically comparable endoscopic POR rates (OR, 0.799, 0.329–1.940; p=0.620).

Eight of the included studies did not stratify patients according to risk groups. In this pooled sample of unselected CD patients, anti-TNFα treatment remained significantly better at preventing clinical (OR, 0.324, 0.158–0.664; p=0.002), endoscopic (OR, 0.225, 0.124–0.409; p<0.001) and severe endoscopic (OR, 0.248, 0.070–0.877) POR.

The relative efficacy of anti-TNFα therapies did not come at the cost of additional safety concerns, according to a pooled analysis of six studies. The rate of adverse (OR, 0.860, 0.457–1.617; p=0.639) and severe adverse (OR, 1.018, 0.641–1.617; p=0.94) events were comparable between patients who received anti-TNFα and other conventional treatments.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.